Testing a drug that may be a treatment for Alzheimer's

Sharon Brangman, MD (photo by Jim Howe) Sharon Brangman, MD (photo
by Jim Howe) Upstate Medical University is screening people who
want to participate in a new, national clinical research study of a
treatment for mild to moderate Alzheimer's disease. Called the T2
Protect AD, the study evaluates the drug troriluzole for its
ability to protect against, slow down or even improve memory and
thinking problems that increase as Alzheimer's progresses. Upstate
Medical University is screening people who want to participate in a
new, national clinical research study of a treatment for mild to
moderate Alzheimer's disease. Called the T2 Protect AD, the study
evaluates the drug troriluzole for its ability to protect against,
slow down or even improve memory and thinking problems that
increase as Alzheimer's progresses. Sharon Brangman, MD Sharon
Brangman, MD, a SUNY Distinguished Service Professor of Medicine
and the chief of the Department of Geriatrics, tells about the
study: -- Participants must be between the ages of 50 and 85 with a
diagnosis of mild to moderate Alzheimer's. -- The study will last
about a year and require nine medical visits. -- Each participant
starts and ends with a magnetic resonance imaging (MRI) brain
scan., a SUNY Distinguished Service Professor of Medicine and the
chief of the Department of Geriatrics, tells about the study: --
Participants must be between the ages of 50 and 85 with a diagnosis
of mild to moderate Alzheimer's. -- The study will last about a
year and require nine medical visits. -- Each participant starts
and ends with a magnetic resonance imaging (MRI) brain scan. Click
her Click her e to learn more about the study or contact the e to
learn more about the study or contact the Center of Excellence for
Alzheimer's Disease at Upstate Center of Excellence for Alzheimer's
Disease at Upstate by calling 315-464-3285. by calling
315-464-3285.